Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
2.580
-0.100 (-3.73%)
Oct 13, 2026, 10:40 AM EDT - Market open
Seres Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.88 | 0.79 | - | - | - | 144.93 | |
Revenue Growth | - | - | - | - | - | 336.33% |
Cost of Revenue | 47.96 | 55.6 | 68.13 | 117.6 | 109.65 | 141.89 |
Gross Profit | -46.08 | -54.82 | -68.13 | -117.6 | -109.65 | 3.04 |
Selling, General & Admin | 32.15 | 39.16 | 53.18 | 77.5 | 70.26 | 69.26 |
Other Operating Expenses | - | - | - | - | - | -1.73 |
Operating Expenses | 32.15 | 39.16 | 53.18 | 77.5 | 70.26 | 67.53 |
Operating Income | -78.23 | -93.97 | -121.32 | -195.1 | -179.91 | -64.49 |
Interest Expense | - | - | - | -2.47 | -6.02 | -2.91 |
Interest & Investment Income | 1.57 | 2.23 | 3.97 | 7.3 | 3.06 | 2.87 |
Other Non Operating Income (Expenses) | 6.51 | 16.59 | 9.29 | -0.1 | -0.02 | -0.55 |
EBT Excluding Unusual Items | -70.14 | -75.16 | -108.06 | -190.37 | -182.89 | -65.08 |
Gain (Loss) on Sale of Investments | - | - | - | 0.24 | -0.69 | -0.5 |
Gain (Loss) on Sale of Assets | 53.49 | 80.85 | 5.68 | - | - | - |
Other Unusual Items | - | - | -23.4 | - | - | - |
Pretax Income | -22.46 | 5.7 | -125.77 | -190.13 | -183.58 | -65.58 |
Earnings From Continuing Operations | -22.46 | 5.7 | -125.77 | -190.13 | -183.58 | -65.58 |
Earnings From Discontinued Operations | - | - | 125.91 | 76.41 | -66.58 | - |
Net Income | -22.46 | 5.7 | 0.14 | -113.72 | -250.16 | -65.58 |
Net Income to Common | -22.46 | 5.7 | 0.14 | -113.72 | -250.16 | -65.58 |
Net Income Growth | - | 4088.24% | - | - | - | - |
Shares Outstanding (Basic) | 9 | 9 | 8 | 6 | 5 | 5 |
Shares Outstanding (Diluted) | 9 | 9 | 8 | 6 | 5 | 5 |
Shares Change | 10.79% | 14.16% | 21.40% | 18.44% | 17.86% | 14.93% |
EPS (Basic) | -2.41 | 0.64 | 0.02 | -17.77 | -46.29 | -14.30 |
EPS (Diluted) | -2.41 | 0.64 | 0.00 | -17.77 | -46.29 | -14.30 |
EPS Growth | - | 14333.92% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -51.3 | 0.87 | -148.99 | -125.33 | -238.64 | -2.88 |
Free Cash Flow Per Share | -5.50 | 0.10 | -19.18 | -19.58 | -44.16 | -0.63 |
Gross Margin | - | - | - | - | - | 2.10% |
Operating Margin | -4154.38% | -11910.14% | - | - | - | -44.50% |
Profit Margin | -1192.94% | 721.93% | - | - | - | -45.25% |
Free Cash Flow Margin | -2724.11% | 109.63% | - | - | - | -1.99% |
EBITDA | -74.78 | -89.84 | -115.85 | -188.85 | -173.29 | -58.55 |
EBITDA Margin | - | - | - | - | - | -40.40% |
D&A For EBITDA | 3.45 | 4.13 | 5.47 | 6.24 | 6.63 | 5.95 |
EBIT | -78.23 | -93.97 | -121.32 | -195.1 | -179.91 | -64.49 |
EBIT Margin | - | - | - | - | - | -44.50% |
Revenue as Reported | 1.88 | 0.79 | - | - | - | 144.93 |